adMare
News
October 02 2024
Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment
September 18 2024
NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases
September 16 2024
Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec
September 05 2024
Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma
September 04 2024
PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada
September 03 2024
SOFIAC Canada enables decarbonization of adMare BioInnovations' buildings with a $3.275M investment
August 27 2024
Find Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Study of FTX-101 for the Treatment of Chronic Optic Neuropathy
August 14 2024
adMare BioInnovations Opens Applications for the Fall Cohorts of the BioInnovation Scientist Programs
July 23 2024
Sutter Health Deploys World’s First Wearable Doppler Ultrasound Patch to Enhance Safety of ICU Patients
July 22 2024
Zymeworks Announces FDA Clearance Of Investigational New Drug Application For ZW191, A Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 405
Toronto, Ontario, Canada
M5G 1M1
T. 416.673.8100
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
